F Giles

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi A pilot study of recombinant human interleukin-4 therapy of myelofibrosis
    F J Giles
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Interferon Cytokine Res 19:1253-5. 1999
  2. ncbi Accelerated and blastic phases of chronic myelogenous leukemia
    Francis J Giles
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428 Houston, TX 77030, USA
    Hematol Oncol Clin North Am 18:753-74, xii. 2004
  3. ncbi Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Leuk Res 29:649-52. 2005
  4. ncbi Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2095-104. 2003
  5. ncbi Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
    Francis J Giles
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, PO Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 28:595-604. 2004
  6. ncbi Outcome of patients with acute myelogenous leukemia after second salvage therapy
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Cancer 104:547-54. 2005
  7. ncbi The emerging role of angiogenesis inhibitors in hematologic malignancies
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:23-9. 2002
  8. ncbi Troxacitabine-based therapy of refractory leukemia
    Francis J Giles
    Section of Developmental Thereputics, The University of Texas M D Anderson Cancer Center, Department of Lukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030 4095, USA
    Expert Rev Anticancer Ther 2:261-6. 2002
  9. ncbi Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2134-41. 2002
  10. ncbi Mammalian target of rapamycin as a therapeutic target in leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Mol Med 5:653-61. 2005

Collaborators

Detail Information

Publications121 found, 100 shown here

  1. ncbi A pilot study of recombinant human interleukin-4 therapy of myelofibrosis
    F J Giles
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Interferon Cytokine Res 19:1253-5. 1999
    ..Other significant toxicities included fever, flu-like symptoms, peripheral edema, and ascites. IL-4 at this schedule was toxic and had no significant activity in myelofibrosis...
  2. ncbi Accelerated and blastic phases of chronic myelogenous leukemia
    Francis J Giles
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428 Houston, TX 77030, USA
    Hematol Oncol Clin North Am 18:753-74, xii. 2004
    ..This article reviews the current diagnostic criteria, therapeutic strategies, outcomes, and investigational therapies for AP and BP CML...
  3. ncbi Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Leuk Res 29:649-52. 2005
    ..There was no significant impact on CR rates, TTF, survival, or toxicity of adding an IL-11 regimen to IA induction in patients >/=50 years of age with AML...
  4. ncbi Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2095-104. 2003
    ..In vitro data on the mechanism of action of GO may be particularly helpful in the design of future clinical studies...
  5. ncbi Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
    Francis J Giles
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, PO Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 28:595-604. 2004
    ..In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD...
  6. ncbi Outcome of patients with acute myelogenous leukemia after second salvage therapy
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Cancer 104:547-54. 2005
    ..The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival...
  7. ncbi The emerging role of angiogenesis inhibitors in hematologic malignancies
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:23-9. 2002
    ..This review will summarize several angiogenesis inhibitors in clinical development...
  8. ncbi Troxacitabine-based therapy of refractory leukemia
    Francis J Giles
    Section of Developmental Thereputics, The University of Texas M D Anderson Cancer Center, Department of Lukemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030 4095, USA
    Expert Rev Anticancer Ther 2:261-6. 2002
    ..Phase II studies in patients with refractory lymphoproliferative diseases are ongoing. Troxacitabine merits further study in patients with hematological malignancies...
  9. ncbi Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2134-41. 2002
    ....
  10. ncbi Mammalian target of rapamycin as a therapeutic target in leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Mol Med 5:653-61. 2005
    ..FLT3, VEGF, and BCR-ABL mediate their activities via mTOR. New rapamycin analogs including CCI-779, RAD001, and AP23573, are entering clinical studies for patients with hematologic malignancies...
  11. ncbi Iseganan HCl: a novel antimicrobial agent
    Francis J Giles
    The University of Texas, MD Anderson Cancer Center, Department of Leukaemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Expert Opin Investig Drugs 11:1161-70. 2002
    ..Future studies will expand on the role of iseganan as a novel antimicrobial...
  12. ncbi Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:656-64. 2002
    ..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
  13. ncbi Novel agents for the therapy of acute leukemia
    Francis J Giles
    Section of Developmental Therapeutics, Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 14:3-9. 2002
    ....
  14. ncbi The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies
    F J Giles
    Department of Leukemia, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 6:32-9. 2001
    ....
  15. ncbi Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study
    F J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 36:57-65. 1999
    ..Ara-C did not add to the activity of the cis-p/fluda combination in this study group...
  16. ncbi Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia
    F J Giles
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 37:87-95. 2000
    ..We conclude that oral idarubicin is sufficiently safe and active to warrant phase II studies investigating it as part of interferon-based regimens in patients with advanced CML...
  17. ncbi Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia
    F Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, Texas 77030 4095, USA
    Invest New Drugs 19:13-20. 2001
    ....
  18. ncbi Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 123:850-7. 2003
    ..The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study...
  19. ncbi Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
    F J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:406-13. 2001
    ..Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy. Outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy...
  20. ncbi A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:2908-17. 2004
    ..As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS)...
  21. ncbi Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival
    F J Giles
    Departments of Leukemia, Biostatistics, and Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 61, Houston, TX 77030, USA
    Leuk Lymphoma 42:67-73. 2001
    ....
  22. ncbi Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
    J Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 36:479-84. 2000
    ..In summary, the CAT regimen is well tolerated and has significant anti-leukemia activity which warrants further investigation...
  23. ncbi High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
    J Cortes
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 92:7-14. 2001
    ....
  24. ncbi Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 50:497-500. 2002
    ..Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML...
  25. ncbi Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  26. ncbi Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid
    E Estey
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 42:309-16. 2001
    ..Nonetheless, the rates and duration of PCR negativity produced by lipoATRA monotherapy suggest that lipoATRA is a superior anti-APL agent than oral ATRA...
  27. ncbi Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA
    I Jilani
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 17:114-9. 2003
    ..Furthermore, the data derived from this study support the notion that the presence of FLT3 ITD in conjunction with the absence of the wild-type FLT3 allele predicts an especially poor prognosis for patients with AML...
  28. ncbi Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6615-24. 2005
    ..A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  29. ncbi Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    Alvaro Aguayo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 95:1923-30. 2002
    ..Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors...
  30. ncbi Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  31. ncbi Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:375-80. 2003
    ..No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study...
  32. ncbi New drugs in acute myeloid leukemia
    Francis J Giles
    Section of Developmental Therapeutics, Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Curr Oncol Rep 4:369-74. 2002
    ..Those agents targeting vascular endothelial growth factor are also briefly reviewed...
  33. ncbi Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  34. ncbi Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia
    J Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 92:2016-22. 2001
    ..In the current study, the authors investigated the use of CsA in the management of anemia or thrombocytopenia of presumed autoimmune etiology associated with CLL...
  35. ncbi Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 2:630-40. 2002
    ..Gemtuzumab ozogamicin-based combinations should not be prescribed outside the research setting until further data is available...
  36. ncbi New agents in myelodysplastic syndromes
    Elias J Jabbour
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77063, USA
    Curr Hematol Rep 4:191-9. 2005
    ..Further development of rational therapies and improvements in the outcome of patients with MDS are likely to emerge from an increased understanding of the pathophysiology of these diseases...
  37. ncbi Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  38. ncbi Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens...
  39. ncbi Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1050-6. 2003
    ..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...
  40. ncbi EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
    Jingxuan Pan
    The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 109:315-22. 2007
    ..We conclude that EXEL-0862 is active against KIT activation loop mutants and is a promising candidate for the treatment of patients with SM and other KIT-driven malignancies harboring active site mutations...
  41. ncbi The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:801-11. 2006
    ..AG-01736 had minimal biologic or clinical activity in this elderly patient population...
  42. ncbi Troxacitabine activity in extramedullary myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston 77030, USA
    Hematology 7:179-85. 2002
    ..Troxacitabine-based therapy had significant antileukemic activity in extramedullary myeloid leukemias and warrants further investigation in this clinical situation...
  43. ncbi Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
    E Jabbour
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
    Leukemia 27:907-13. 2013
    ..Even in the presence of poor disease characteristics, nilotinib provided significant clinical benefit in patients with imatinib-resistant or -intolerant CML. This system may yield insight on the prognosis of patients...
  44. ncbi Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML)
    F Ravandi
    Leukemia Department, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Leuk Res 31:791-7. 2007
    ..04). Other mechanisms may be responsible for abnormal phosphorylation of FLT3 and inhibitors of FLT3 should also be investigated in patients without mutations...
  45. ncbi Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
    Efrosyni Apostolidou
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:887-91. 2003
    ..The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML...
  46. ncbi Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:1091-6. 2003
    ..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
  47. ncbi Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:813-22. 2006
    ..The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks...
  48. ncbi Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients...
  49. ncbi A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
    Francis J Giles
    M D Anderson Cancer Center, Department of Leukemia, The University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 28:559-65. 2004
    ..A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study...
  50. ncbi Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1920-8. 2003
    ..SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2...
  51. ncbi Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Cancer Chemother Pharmacol 51:87-90. 2003
    ..A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML...
  52. ncbi Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    E Jabbour
    Department of Leukemia, The University of Texas, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 20:1767-73. 2006
    ..In conclusion, P-loop mutations were not associated with poor outcome, suggesting that the prognosis of patients who fail imatinib is multifactorial...
  53. ncbi Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease
    Apostolia M Tsimberidou
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 44:1719-25. 2003
    ..Human antimouse antibody (HAMA) and/or human antiricin antibody (HARA) development was documented in 2 patients. Anti-B4 blocked ricin was well tolerated but had limited activity in patients with residual CLL after chemotherapy...
  54. ncbi Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 52:229-34. 2003
    ....
  55. ncbi Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia and Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 72, Houston, TX 77030, USA
    Blood 99:2265-7. 2002
    ..008). Multivariate analysis showed that VEGF was not independent of the synthesis stage (P =.09). These data suggest that VEGF plays a role in the biology of CML and that VEGF inhibitors should be investigated in CML...
  56. pmc Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
    Zhihong Zeng
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 109:3509-12. 2007
    ..Our study provides the first evidence that rapamycin derivatives inhibit AKT signaling in primary AML cells both in vitro and in vivo, and supports the therapeutic potential of mTOR inhibition strategies in leukemias...
  57. ncbi Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
    Nada Orsolic
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston 77030 4009, USA
    Br J Haematol 124:727-38. 2004
    ..These data indicate that the combination of troxacitabine and IM has significant preclinical activity in advanced CML and that clinical evaluation of this combination is warranted...
  58. ncbi The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
    Francis J Giles
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:624-7. 2007
    ..001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy...
  59. ncbi A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Box 428, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 28:353-7. 2004
    ..Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML...
  60. ncbi SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  61. ncbi A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)
    Francis J Giles
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 44:1165-72. 2003
    ..6 and 2.0 (P = 0.0131). Iseganan was well tolerated; no systemic absorption was detected. Iseganan is safe and may be effective in reducing UOM and its clinical sequelae...
  62. ncbi MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, 1400 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:500-2. 2007
    ..The observation of responses in 3 patients with T315I phenotype-refractory CML or Ph-positive ALL, at doses of MK-0457 associated with no significant extramedullary toxicity, is very encouraging...
  63. ncbi More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia
    Y O Huh
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Leukemia 16:2249-52. 2002
    ..The data suggest that RAEB-T is more likely to be an advanced stage of MDS and biologically different from AML...
  64. ncbi Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies
    Jean Pierre J Issa
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 103:1635-40. 2004
    ..There was no correlation between P15 methylation at baseline or after therapy and response to decitabine. We conclude that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses...
  65. ncbi Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
    ..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease...
  66. ncbi In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin
    Dawn E Colburn
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hematology 9:217-21. 2004
    ..Azole antifungal agents are increasingly used in this context. In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin...
  67. ncbi Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:522-8. 2003
    ..Decitabine is a hypomethylating agent that has shown encouraging preliminary anti-CML activity. This study evaluated the activity and toxicity of decitabine in different phases of CML...
  68. ncbi Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
    Apostolia Maria Tsimberidou
    Department of Leukemia, Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2343-51. 2006
    ..The purpose of this study was to assess the incidence, presenting characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response and survival...
  69. ncbi Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Expert Rev Anticancer Ther 2:437-48. 2002
    ..g., triapine) are being evaluated in clinical trials...
  70. ncbi Management of intracranial fungal infections in patients with haematological malignancies
    Gloria Mattiuzzi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 131:287-300. 2005
    ....
  71. ncbi Clinical experience with decitabine in North American patients with myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Hematol 84:18-24. 2005
    ....
  72. ncbi The role of gemtuzumab ozogamicin in acute leukaemia therapy
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 132:398-409. 2006
    ..The future of GO is its use in combination with other cytotoxic agents. Ongoing clinical trials may better define the role of GO combinations, particularly in untreated AML...
  73. ncbi Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 101:3413-5. 2003
    ..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
  74. ncbi Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
  75. ncbi Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, Houston, TX 77030, USA
    Leuk Res 27:1077-83. 2003
    ..Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies...
  76. ncbi DNA methylation in haematological malignancies: the role of decitabine
    Bryan T Hennessy
    Department of Leukaemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Opin Investig Drugs 12:1985-93. 2003
    ..Phase II and III studies are currently ongoing to evaluate decitabine, both alone and in combination, in various stages of these haematological malignancies...
  77. doi High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
    Jorge E Cortes
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:4754-9. 2009
    ..Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML)...
  78. ncbi Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 108:45-51. 2006
    ..However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation...
  79. ncbi Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors
    Gautam Borthakur
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:800-5. 2007
    ..Thus, the incidence of IA among CLL patients treated with FCR was comparable with historical rates. The diagnosis of AIHA can be considered even if the DAT is negative. Pre-existing AIHA need not preclude front-line FCR therapy...
  80. ncbi Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:4343-9. 2002
    ..Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome...
  81. ncbi Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:120-7. 2006
    ..Vincristine is an important component of ALL therapy. In animal models, the encapsulation of vincristine into sphingomyelin liposomes or "sphingosomes" for injection (SV) has improved efficacy compared with conventional vincristine...
  82. ncbi Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 99:4222-4. 2002
    ..A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible...
  83. pmc Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
    Hagop M Kantarjian
    Leukemia Department, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 116:3163-70. 2010
    ..0035) compared with placebo. Grade 3 rash and arthralgia each were reported in 1 romiplostim-treated patient (4%). This study suggests romiplostim may provide clinical benefits in MDS patients during azacitidine therapy...
  84. ncbi Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2177-87. 2002
    ..We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival...
  85. ncbi Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit
    Srdan Verstovsek
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, United States
    Leuk Res 30:1365-70. 2006
    ....
  86. doi Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:985-94. 2008
    ..Patterns of KD mutations in Philadelphia chromosome (Ph)-positive acute lympho- blastic leukemia (ALL) are less well studied...
  87. ncbi Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis
    Dawn E Colburn
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, USA
    Hematology 7:187-8. 2002
    ..As in these patients, local therapy for skin disease may delay or obviate the need for systemic therapy in B-CLL...
  88. ncbi Eradication of minimal residual disease in hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:4658-62. 2006
    ..Disease characteristics may potentially be used to identify patients that are more likely to benefit from such additional therapy...
  89. doi Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome
    Razelle Kurzrock
    Phase I Program, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Cancer Res 14:509-14. 2008
    ..To determine the safety and describe the antitumor activity of tipifarnib in patients with myelodysplastic syndrome (MDS) using an alternate-week schedule...
  90. ncbi Thalidomide therapy for myelofibrosis with myeloid metaplasia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1974-84. 2006
    ..Thalidomide is a putative antiangiogenesis agent with activity in several hematologic malignancies...
  91. ncbi Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Leuk Res 30:1499-505. 2006
    ..In addition, both drugs inhibited the phosphorylation of PDGFR-alpha tyrosine kinase with equivalent efficacy. We conclude that AMN107 and imatinib are active and equipotent against cells expressing the FIP1L1-PDGFR-alpha fusion gene...
  92. ncbi Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 100:1590-5. 2002
    ..We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD...
  93. pmc Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies
    Gloria N Mattiuzzi
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Antimicrob Agents Chemother 50:143-7. 2006
    ..In conclusion, intravenous itraconazole and caspofungin provided similar protection against invasive fungal infection during induction chemotherapy, and both drugs were well tolerated...
  94. ncbi Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3547-53. 2002
    ..04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML...
  95. ncbi Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    Deborah A Thomas
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 123:436-41. 2003
    ..Thalidomide analogues with more potent immunomodulatory activities and more favourable toxicity profiles may offer more promise as anti-AML therapy...
  96. ncbi Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2636-42. 2003
    ..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
  97. ncbi Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
    Susan M O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2657-63. 2003
    ..The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti-CD52 monoclonal antibody, in patients with B-cell chronic lymphocytic leukemia and residual disease after chemotherapy...
  98. ncbi Phase II study of alemtuzumab in chronic lymphoproliferative disorders
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:773-8. 2003
    ..Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders...
  99. ncbi Monoclonal antibodies in the treatment of lymphoid leukemia
    Susan O'Brien
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Drugs Today (Barc) 39:541-50. 2003
    ..Further understanding of the in-vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach...
  100. ncbi Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  101. ncbi Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...